Hispanic/Latino gastric adenocarcinoma patients have distinct molecular profiles including a high rate of germline CDH1 mutations
Gene sequencing revealed a high rate of mutations that raise the risk of gastric cancer among people of hispanic origins, according to... Read More
Oesophageal and proximal gastric adenocarcinomas are rare after detection of Helicobacter pylori infection
A study of more than 36,000 people with H. pylori raises questions about the long-held belief that eradicating the infection lowers the... Read More
Low-Dose Aspirin Might Lower Odds for Digestive Cancers
Low-dose aspirin may reduce the risk of digestive tract cancers, including gastric cancer, according to European researchers who analyzed 113 studies and... Read More
YAP1 mediates gastric adenocarcinoma peritoneal metastases that are attenuated by YAP1 inhibition
A new study led by GCF grant recipient Jaffer Ajani of MD Anderson found a link between the cancer-associated gene YAP1 and... Read More
Phase I Escalation and Expansion Study of Bemarituzumab (FPA144) in Patients With Advanced Solid Tumors and FGFR2b-Selected Gastroesophageal Adenocarcinoma
Five Prime Therapeutics’ investigational drug bemarituzumab showed promising efficacy in the late-line treatment of gastroesophageal junction adenocarcinoma.
GCF Grant Recipient, Jaffer Ajani, MD, Speaks on the Rapidly Evolving Science of Gastric Cancer
Check out GCF grant recipient Jaffer Ajani of MD Anderson in this video presentation on the rapidly evolving science of gastric cancer
Safety and efficacy of pembrolizumab in combination with S-1 plus oxaliplatin as a first-line treatment in patients with advanced gastric/gastroesophageal junction cancer: Cohort 1 data from the KEYNOTE-659 phase IIb study
In a small trial, Keytruda combined with S-1 and oxaliplatin showed encouraging efficacy in the first-line treatment of gastric cancer.
Cisplatin, fluorouracil in bolus injection, and leucovorin in first-line therapy for advanced gastric cancer as an alternative to protocols with infusional fluorouracil
A chemo regimen containing fluorouracil, cisplatin and leucovorin outperformed continuous use of fluorouracil in a Brazilian study of gastric cancer patients
Biomarker analyses of second-line ramucirumab in patients with advanced gastric cancer from RAINBOW, a global, randomized, double-blind, phase 3 study
A study showed that Cyramza with paclitaxel improved survival in gastric cancer over paclitaxel alone.
New markers and models of premalignancy and the early development of gastric cancer
Using a new model of stomach pre-cancers in mice, Dana-Farber researchers gained important insights into the early events that lead to the... Read More
